Drug Information

Drug General Information
Drug ID
D0K5LQ
Former ID
DAP001064
Drug Name
Pemirolast
Synonyms
Pemirolastum; Pemirox; Pemirolast [INN]; Pemiroplast Potassium; Alamast (TN); Alegysal (TN); Pemirolast (INN); Pemirolastum [INN-Latin]; Pemirox (TN); 9-TBX; 9-methyl-3-(1H-tetrazol-5-yl)-4H-pyrido(1,2-a)pyrimidin-4-one; 9-methyl-3-(2H-tetrazol-5-yl)pyrido[1,2-a]pyrimidin-4-one
Drug Type
Small molecular drug
Indication Allergic conjunctivitis [ICD9: 204.0, 372.0, 372.14, 995.3; ICD10:C91.0, H10, H10.45, T78.4] Approved [536119], [542352], [551871]
Therapeutic Class
Antiallergic Agents
Structure
Download
2D MOL

3D MOL
Formula
C10H8N6O
InChI
InChI=1S/C10H8N6O/c1-6-3-2-4-16-9(6)11-5-7(10(16)17)8-12-14-15-13-8/h2-5H,1H3,(H,12,13,14,15)
InChIKey
HIANJWSAHKJQTH-UHFFFAOYSA-N
CAS Number
CAS 100299-08-9
PubChem Compound ID
57697
PubChem Substance ID
8185373, 14773738, 14822841, 43115342, 46509034, 50065081, 50563413, 57313910, 85209679, 93166875, 96024435, 104313292, 123092154, 128063839, 131269071, 134338322, 135035415, 137007584, 137035161, 142971147, 160964226, 162178777, 164814579, 175268367, 178103901, 179150951, 179326618, 223797099, 226416213, 252355732
Target and Pathway
Target(s) Histamine H1 receptor Target Info Antagonist [536707]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Inflammatory mediator regulation of TRP channels
PANTHER Pathway Histamine H1 receptor mediated signaling pathway
Reactome Histamine receptors
G alpha (q) signalling events
WikiPathways Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
IL-4 Signaling Pathway
Gastrin-CREB signalling pathway via PKC and MAPK
GPCR ligand binding
GPCR downstream signaling
References
Ref 536119Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20.
Ref 542352(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7329).
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 536707The effect of a combined therapy with a histamine H1 antagonist and a chemical mediator release inhibitor on allergic conjunctivitis. Ophthalmologica. 2008;222(4):232-9. Epub 2008 May 8.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.